Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

PMA ADOPTS ADVICE AGAINST MD ACCEPTANCE OF DRUG INDUSTRY GIFTS in cases where prescribers' objectivity appears to be threatened. In a May 30 announcement, the Pharmaceutical Manufacturers Association said it "endorsed" guidelines on industry-physician relations developed by the American College of Physicians. PMA President Gerald Mossinghoff said in the announcement that ACP "has developed a solid framework to preserve the integrity of the interactions between physicians and industry." The PMA-endorsed position states that "gifts, hospitality or subsidies offered to physicians by the pharmaceutical industry ought not to be accepted if acceptance might influence or appear to others to influence the objectivity of clinical judgment." The statement advises that " a useful criterion in determining acceptable activities and relationships" is whether a physician would "be willing to have these arrangements generally known." The PMA board agreed to adopt ACP's position paper as part of the "PMA Code of Pharmaceutical Marketing Practices." The college published four statements on physician-industry interactions in the April 14 issue of Annals of Internal Medicine. The issue of marketing practices is timely because of rumblings from Capitol Hill. Sen. Kennedy (D-Mass.) is believed to be preparing an oversight hearing on marketing practices for sometime this summer before his Senate Labor & Human Resources Committee. Kennedy's staff had initially indicated interest in hearings on drug promotional issues in early June. If no hearing develops this year, Kennedy's committee may issue a report based on the survey conducted of major pharmaceutical manufacturers last year. ACP's guidelines advise that when drug manufacturers supply funding for continuing medical education programs, independent institutions and organizations that provide accreditation for such programs "should develop and enforce explicit policies to maintain complete control of program content." The guides also urged professional societies to develop policies to "discourage excessive industry-sponsored gifts, amenities and hospitality to physicians at meetings."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts